The latest articles from BioStock
» BioStock studio interview: AcuCort on promising news from the Swedish Medical Products Agency
» Idogen's CEO on the ongoing share issue
» Toleranzia takes no shortcuts in scaling up production of TOL2
» Increased international activity in mitochondrial diseases
» RhoVac's immunotherapy targets a huge patient group
» Redsense blood leak alarm gains ground in the US
Read BioStock's latest newsletter for week 9 here.
Thermo Fisher has bid in German qiagen equivalent to 11,6 billion USD. Read more.
Enzymatica has reported strong results from the preventive use of ColdZyme against cold viruses. Read more.
Cyxone is investigating the possibility of changing the list to Nasdaq Main Market Nordic Small Cap. Read more.
The Swedish Companies Registration Office has granted permission to implement the merger plan between Klaria and Caress. Read more.
Fluicell has received a breakthrough order and entered into a cooperation agreement regarding Biopixels w/ University of Canterbury. Read more.
BioInvent and Transgene. will present data on BT 001, an oncolytic virus expressing an anti-CTLA4 antibody, at upcoming conferences. Read more.
BioArctic has announced that Alzheimer's patients in Sweden will be included in the ongoing phase III study of the drug candidate BAN2401. Read more.
Opposite has published a memorandum regarding the rights issue. Read more.
DBP International The rights issue was oversubscribed. Read moreThe company has also carried out a directed new share issue of SEK 15,5 million. Read more.
Reports/Communiqués:
IRRAS
Notices of meetings:
Episurf Medical ObsteCare
News received since yesterday:
CHMP has given a positive opinion for Takeda's Alunbrig (Brigatinib) as first-line treatment of ALK-positive advanced non-small cell lung cancer. Read more.
NDA accelerator and BioStock has entered into a collaboration on communication services for biotechnology companies in the Nordic region. Read more.
Dicot has launched a new website. Read moreThe company will also present at the Life Science Day in Gothenburg on March 4. Read more.
Vitrolife has made an estimate of the impact of the Coronavirus on sales. Read more.
Bone support has carried out a new issue and repurchase of C shares for share savings programs. Read more.
Italian authorities have granted patent protection for S2Medicals ivaQtechnology in Italy. Read more.
Ascelia Pharma has carried out a new issue and repurchase of C shares for share savings programs. Read more.
Diamyd Medical has announced that a new study with Diamyd in autoimmune diabetes has started recruiting patients in Norway. Read more.
Bactiguard has completed the acquisition of Vigilance. Read more.
GASPOROX has received an additional order of SEK 350 relating to previous orders for 000. Read more.
Arjo's The new CFO will take office on March 16. Read moreThe company has also invited to a capital markets day on May 13. Read more.
Contigo Care has announced a continued expansion of Previct within Swedish addiction treatment. Read more.
Karo Pharma has completed the acquisition of the product portfolio from Leo Pharma. Read more.
Orion Corporation has reported the transfer of 94 of its own class B shares to individuals in the company's incentive program. Read more.
Danske Bank has flagged in Orphazyme. Read more.
Novo Nordisk has reported transactions in the share repurchase program. Read more.
This morning's winner: Curando Nordic 40,3%, Fluicell 18,8%, FluoGuide 14%, Genovis 13,9%, Klaria Pharma 12,9%
This morning's losers: Kontigo Care -7,4%, PledPharma 4,9%, Expres2ion Biotech -4,6%, Doxa 4,3%, Respiratorius 4,2%
Index: OMXS30 +2,29% Healthcare +2,65%
More articles from BioStock